Role of P-glycoprotein and organic anion transporting polypeptides in drug absorption and distribution focus on h1-receptor antagonists

Clinical Drug Investigation

Volumn 21, Issue 8, 2001, Pages 587-596

  Hansten, P D ^a   Levy, R H ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANTIDIARRHEAL AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ASTEMIZOLE; CARDIAC GLYCOSIDE; CARRIER PROTEIN; CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; DAUNORUBICIN; DIGOXIN; ERYTHROMYCIN; ESTROGEN; FEXOFENADINE; GLYCOPROTEIN P; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; PACLITAXEL; POLYPEPTIDE; PROGESTERONE; PROTEINASE INHIBITOR; RIFAMPICIN; STEROID; TACROLIMUS; TALINOLOL; TERFENADINE; UNINDEXED DRUG; VALSPODAR;

AEROBIC METABOLISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG TRANSPORT; ENZYME ACTIVITY; FOOD DRUG INTERACTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0034859696     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200121080-00008     Document Type: Review

References (60)

1. Allergic rhinitis: Epidemiology and natural history
2. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin
3. Torsades de pointes occurring in association with terfenadine use
4. Update: Clinically significant cytochrome P-450 drug interactions
5. Fexofenadine
6. max and AUC of fexofenadine by 30%
7. Role of P-glycoprotein in drug disposition
8. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver
9. Functional characterization of the basolateral rat liver organic anion transporting polypeptide
10. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
11. P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs
12. Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene
13. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
14. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs
15. Grapefruit juice selectively inhibits OATP not P-glycoprotein
16. Full blockade of intestinal P-glycoprotein and extensive inhibition of bloodbrain barrier P-glycoprotein by oral treatment of mice with PSC833
17. Brain microvascular P-glycoprotein and a revised model of multidrug resistance in brain
18. ABC transporters in lipid transport
19. Membrane transport of mycophenolate mofetil and its active metabolite, mycophenolic acid in MDCK and MDR1-MDCK cell monolayers
20. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine
21. Reversal of acquired resistance to doxorubicin in K562 human leukemia cells by astemizole
22. Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein
23. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
24. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
25. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers
26. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
27. Substantial excretion of digoxin via the intestinal mucosa and prevention of longterm digoxin accumulation in the brain by the mdr 1a P-glycoprotein
28. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bio-availability of cyclosporine
29. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
30. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans
31. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells
32. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)
33. St. John's wort induces intestinal and hepatic CYP3A4 and P-glycoprotein in healthy volunteers
34. Effects of acute and chronic Saint John's wort (SJW) administration of fexofenadine (FEX) disposition
35. Expression cloning of a rat liver Na(+)-independent organic anion transporter
36. IsolatiOn of a multispecific organic anion and cardiac glycoside tansporter from rat brain
37. Transport of temocaprilat into rat hepatocytes: Role of organic anion transporting polypeptide
38. The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein
39. Stable inducible expression of a functional rat liver organic anion transport protein in HeLa cells
40. Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver
41. Immunologic distribution of an organic anion transport protein in rat liver and kidney
42. The choroid plexus epithelium is the site of the organic anion transport protein in the brain
43. The peptide-based thrombin inhibitor CRC 220 is a new substrate of the basolateral rat liver organic anion-transporting polypeptide
44. Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver
45. Estradiol 17-beta-D-glucuronide is a high-affinity substrate for oatp organic anion transporter
46. -exchange
47. Localization and function of the organic anion-transporting polypeptide Oatp2 in rat liver
48. Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2
49. Immunohistochemieal distribution and functional characterization of an organic anion transporting polypeptide 2 (oatp2)
50. Citrus juices are potent inhibitors of intestinal OATP but not P-glycoprotein
51. Reduction of fexofenadine bioavailability by fruit juices
52. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
53. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein
54. Effect of erythromycin and tumour necrosis factor on the drug resistance of multidrug-resistant cells: Reversal of drug resistance by erythromycin
55. Cardiovascular safety of second-generation antihistamines
56. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine Hi receptor antagonist. 1st communication: Receptor selectivity, antihistaminic activity, and antiallergenic effects
57. 1 receptor antagonist: 2nd communication: Lack of central nervous system and cardiovascular effects
58. Lack of electrocardiographic interaction between desloratadine and erythromycin
59. Lack of electrocardiographic effects when desloratadine and ketoconazole are coadministered